Anafril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anafril

Property Description
Active ingredient Clomipramine Hydrochloride
Form Capsules, Oral Tablets (Sustained-release forms)
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Modulating specific neurochemical pathways
Origin Synthetic (Dibenzazepine derivative)

Clomipramine Hydrochloride: Defining the Drug Entity

Anafril is a synthetic single-component medicine defined by its active ingredient, Clomipramine Hydrochloride (Clomipramine INN), which is supplied as a prescription-only medicine. The product is manufactured for systemic administration in oral dosage forms, primarily as capsules and tablets, including sustained-release preparations. This substance is established in clinical use and is identified as a tertiary amine compound. The drug is characterized by its neurochemical profile as a dibenzazepine derivative.

What Type of Medicine is Anafril?

Anafril is classified as a Tricyclic Antidepressant (TCA), positioning it as an antidepressant agent intended to modulate central nervous system activity. The active compound, Clomipramine, is clinically recognized for its powerful effects on key neurotransmitters. Its mechanism of action is rooted in monoamine reuptake inhibition, a process where the psychoactive substance regulates the availability of neurochemical messengers in the brain. This classification means the medicine is designed to help rebalance the brain’s crucial chemical signals, such as supporting the restoration of emotional equilibrium in patients experiencing significant mood changes. Specifically, Clomipramine is noted for its powerful Serotonin (5-HT) reuptake blockade alongside secondary Norepinephrine (NE) reuptake inhibition, a profile that establishes the drug's distinctive purpose.

Regulatory References

  1. Clomipramine - StatPearls - NIH

What side effects are possible with Anafril?

Possible side effects and safety information

The safety profile for Anafril (Clomipramine) is defined by governmental regulatory documents, which categorize known adverse reactions by frequency and the body system affected. These classifications reflect how the medicine’s risks are officially organized and communicated.


Adverse Reaction Scope

Adverse reactions are broadly grouped by System-Organ-Classes (SOC) including Nervous System Disorders, Psychiatric Disorders, Gastrointestinal Disorders, and Cardiac Disorders.

  • Very Common (Affecting ge 1 in 10 patients): Documented effects often involve central nervous system and anticholinergic responses such as drowsiness, dry mouth, dizziness, tremor, sedation, and constipation.
  • Common (Affecting ge 1 in 100 patients): These include reactions like weight gain, tachycardia, headache, postural hypotension, and specific forms of sexual dysfunction.

Serious Adverse Reactions and Safety Restrictions

Regulatory agencies define specific, clinically significant safety concerns that require attention:

  • Serious Reactions: These include the potential for seizures/convulsions, the risk of Serotonin Syndrome (especially when used with other serotonergic agents), and the potential for severe cardiac arrhythmias.
  • Suicidality Risk: Official labeling includes warnings regarding an increased risk of suicidal thinking and behavior in specific populations, notably children, adolescents, and young adults.

Safety limitations explicitly stated in regulatory texts include a contraindication during the acute recovery period following a recent myocardial infarction and for patients currently taking Monoamine Oxidase Inhibitors (MAOIs). Additionally, adverse effects are often observed to be more frequent at the start of treatment and during dose escalation.

Overdose and Emergency Response

Overdose and When to Seek Help

Anafril (clomipramine) overdose can be fatal and constitutes a medical emergency. Immediate, urgent medical attention is required if an overdose is suspected. Contact emergency medical services or a poison control center right away.

Documented Overdose Symptoms

The most critical manifestations of an overdose primarily affect the cardiovascular and central nervous systems. Symptoms may include:

  • Cardiac Issues: Irregular or rapid heartbeats, potentially life-threatening arrhythmias (such as Torsades de pointes), conduction disorders, severe hypotension (low blood pressure), or cardiac arrest.
  • Neurological Signs: Seizures, coma (loss of consciousness), extreme drowsiness, restlessness, loss of coordination (ataxia), enhanced reflexes, or muscle rigidity.
  • Other Severe Effects: Respiratory depression (slowed breathing), cyanosis (bluish discoloration of the skin), fever, severe sweating, and widening of the pupils (mydriasis).

Key Overdose Risks

Serious toxicity and death can occur from relatively low doses of this type of antidepressant. The risk of life-threatening events is significantly increased if Anafril is taken with a Monoamine Oxidase Inhibitor (MAOI), which can lead to a hyperpyretic crisis, seizures, coma, and death. Intentional overdose is a known risk in patients with depression, emphasizing the need for prescriptions to be for the smallest practical quantity.

Therapeutic Uses of Anafril

What Anafril Treats: Main Uses and Benefits

Anafril (Clomipramine) is considered relevant for managing symptoms in clinical settings that involve heightened or complex symptom patterns, and it is used to provide supportive therapeutic benefits where functional stability becomes affected. The medicine is commonly used across conditions presenting with disruptive manifestations, particularly Obsessive-Compulsive Disorder (OCD), Panic Disorder, and Major Depressive Disorder.

The medicine is indicated for the treatment of obsessions and compulsions in patients with OCD. The therapeutic benefit is that it helps ease the overall symptom burden by helping to address symptom clusters that may become intense or disruptive, such as those related to recurrent thoughts, repetitive actions, mood changes, and episodic anxiety. It also has a clinical application in specific neurological contexts, including management for cataplexy associated with narcolepsy.

Quick Fact: Obsessive-Compulsive Symptoms are the main area of therapeutic focus, where Anafril may help patients cope more steadily with repetitive thoughts and actions.


Anafril is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that supports patients during episodes of heightened discomfort and helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Anafril?

Eligibility for Anafril (Clomipramine) is strictly defined by regulatory documents, establishing populations for whom the medicine is either approved, restricted, or strictly prohibited.

Contraindicated Populations

Use is absolutely contraindicated in patients with a known hypersensitivity to Clomipramine or any tricyclic antidepressant (TCA). It must not be used by patients receiving or who have received a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days or by patients during the acute recovery phase following a Myocardial Infarction.

Age-Related Eligibility

Anafril is approved for the treatment of Obsessive-Compulsive Disorder (OCD) in adults and in children and adolescents 10 years of age and older. Safety and efficacy are not established for children under 10. Older adults require caution due to a higher frequency of decreased organ function, necessitating careful use.

Condition-Based Restrictions

Use is prohibited for patients with severe liver disease or any degree of heart block or cardiac arrhythmias. Caution is mandatory for those with a history of convulsive disorders or significantly impaired renal function. For women, the drug is not recommended during pregnancy unless the benefit outweighs the risk, and a decision must be made to discontinue nursing or discontinue the drug while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Anafril (clomipramine) may interact with a variety of other medicinal products, leading to changes in drug concentrations or additive effects. This section outlines officially documented interactions, excluding information on symptoms, dosing, or therapeutic use.

Contraindicated Combinations and Timing Restrictions

Category Practical Constraint
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated. A 14-day washout period is required when switching between Anafril and MAOIs intended for psychiatric use, or when using MAOIs like linezolid or methylene blue.
Selective MAO-A Inhibitors (e.g., moclobemide) Contraindicated due to risk of severe reactions.

Interactions Affecting Drug Metabolism

Co-administration with potent inhibitors of the enzyme systems Cytochrome P450 1A2 (CYP1A2, e.g., fluvoxamine) or Cytochrome P450 2D6 (CYP2D6, e.g., quinidine) can increase the plasma concentrations of clomipramine and its active metabolite. This may require close observation by a healthcare professional.

Interactions with Additive Effects

Anafril's use with other medications requires caution due to potential for additive effects in the following areas:

  • CNS Depressants: Combined use with alcohol, opioids, sedatives, or general anesthetics can increase central nervous system depression.
  • Anticholinergic Agents: Use with other anticholinergics can increase the risk of effects like urinary retention.
  • QTc-Prolonging Drugs: Concomitant use with medications known to prolong the QTc interval (e.g., amiodarone) is generally avoided due to increased risk of serious heart rhythm changes.
  • Sympathomimetics: Anafril may either increase or decrease the effects of co-administered sympathomimetic agents.

Mechanism of Action

Modulating Serotonin and Norepinephrine Balance

This drug primarily functions by inhibiting the reuptake of two key neurotransmitters, serotonin and norepinephrine, within the central nervous system. By blocking the reuptake transporters ( SERT and NET), it increases the concentration of these chemical messengers in the nerve synapses. This action modifies the overall signaling activity in circuits related to monoamine transmission, ultimately affecting long-term nerve cell signaling and neurocircuitry function.


Secondary Receptor Interference

Beyond its primary action, the drug engages secondary mechanisms by acting as an antagonist (blocker) at several other receptors, including muscarinic acetylcholine, histamine H1, and alpha-1 adrenergic receptors. This off-target binding initiates and suppresses signaling sequences in different pathways. Blocking these receptors leads to peripheral and central physiological adjustments, such as interference with parasympathetic nerve activity and contributing to changes in histaminergic system activity and alpha-adrenergic regulation.

Dosage and Administration Information

Anafril (Clomipramine Hydrochloride) is administered primarily via the oral route, available as capsules and tablets, including sustained-release forms. The medicine is utilized according to a structured protocol involving initial titration and maintenance dosing.

Treatment for adults typically begins with a low initial dose of 25 mg once daily. This amount is gradually increased over the first two weeks toward 100 mg per day, with the maximum recommended adult dose being 250 mg daily. Initially, the daily total may be taken in divided doses to aid gastrointestinal tolerance. The maintenance dose is often consolidated into a single dose at bedtime to manage potential drowsiness. The medicine can be administered with or without food.

Specific dosing rules are defined for certain populations. Older adults are advised to initiate treatment with a lower starting amount of 10 mg daily, with subsequent adjustments made cautiously. For pediatric patients (age ge 10 years), the dose starts at 25 mg daily, with the maximum dose capped at the lesser of 200 mg or 3 mg/kg per day. Administration requires the swallowing of sustained-release tablets whole, as these preparations must not be crushed or halved. Clinical protocols specify that treatment be ended by a gradual reduction (tapering) of the dosage.

Recent Clinical Evidence

Research evidence / Overview of studies for Anafril


Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Research concerning Anafril (Clomipramine) has primarily concentrated on studies exploring how symptoms change over time for Obsessive-Compulsive Disorder (OCD). The core evidence for this use comes primarily from Randomized Controlled Trials (RCTs). These studies typically compare Clomipramine with a neutral substance (placebo) or sometimes against other medicines. Researchers examined outcomes related to symptom intensity or variability, mainly by measuring changes on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), a standardized tool for symptom assessment.

Research so far indicates that studies reported a pattern of measured symptom change on the Y-BOCS scale over the short-term study periods, which often lasted between eight and ten weeks. The findings describe patterns observed in these short-term studies, and some regulatory reviews have described the consistency of the reported observations in the available RCTs.


Evidence for Other Clinical Situations Studied

Anafril was also evaluated in research relevant in trials assessing short-term or episodic symptom patterns for several other conditions. For Cataplexy associated with Narcolepsy, research was applied in studies examining episodic or acute symptom patterns in adults. Data show patterns related to the frequency of these episodes, which was measured during the study period, although the evidence base relies more on cohort studies and small clinical trials.

For Major Depressive Disorder (MDD), Clomipramine was studied for conditions characterized by fluctuating manifestations. The available trials are often older, and comparative evidence is lacking against many of the newer treatments introduced since those trials were conducted.


What Is Still Uncertain About Anafril Research

Follow-up durations were limited in many controlled settings, leaving a gap in understanding the full spectrum of long-term outcomes. Furthermore, evidence quality varies across studies, with methodological limitations observed in some older trials. Data for certain groups, such as older adults, remain insufficient, and another gap is the limited comparative evidence against newer generation medicines.

Key Studies & References

  1. Clomipramine and fluoxetine effects in the treatment of panic disorder (Panic Disorder RCT)

Frequently Asked Questions (FAQ)

Common questions about Anafril (FAQ)


Q: What is the typical timeframe before a person starts to feel the therapeutic effects of Anafril?

A: Studies and official information indicate that while some people may notice initial changes in symptoms within the first one to two weeks, the full therapeutic effect may take several weeks to become noticeable.

Q: Is there a known link between Anafril and changes in body weight or appetite?

A: Yes, official drug information states that weight increase is a commonly reported side effect. Additionally, changes in appetite are noted, with some patients reporting increased appetite and others reporting anorexia (loss of appetite).

Q: What are the possible withdrawal symptoms if Anafril is stopped suddenly?

A: Regulatory documents advise against abruptly stopping Anafril to prevent withdrawal reactions or syndrome. Official guidance emphasizes that the dosage should be gradually reduced and tapered to safely discontinue the medication.

Q: What vision-related changes, like blurred vision, are associated with Anafril use?

A: Vision changes are known side effects. Regulatory labeling lists blurred vision and abnormal accommodation (difficulty focusing). The medication also carries warnings regarding the potential risk of angle-closure glaucoma.

Q: What types of medications are known to have significant interactions with Anafril?

A: Significant interactions are documented for medicines that affect liver enzymes (such as CYP1A2 or CYP2D6 inhibitors), drugs that prolong the QTc interval (which affects heart rhythm), and agents with CNS depressant or anticholinergic properties.

Q: Is it safe to take Anafril with common over-the-counter pain relievers?

A: While no specific regulatory interaction was found in some reports for clomipramine and acetaminophen (Paracetamol), drug interactions may exist with other non-prescription products. Patients should consult a healthcare provider regarding all medications, including non-prescription ones.

Q: How does Anafril compare to SSRIs in terms of side effect profile?

A: As a tricyclic antidepressant (TCA), Anafril’s side effect profile is distinct from newer drugs. The official label reports a higher incidence of classic TCA side effects, such as dry mouth, constipation, drowsiness, and sexual dysfunction.

Q: What are the differences between the brand name Anafril and the generic clomipramine?

A: The FDA and other regulatory bodies have approved generic versions of clomipramine hydrochloride. These generic products are required to be bioequivalent to the brand-name Anafril, meaning they meet the same quality standards and work the same way in the body.

Q: Is it better to take Anafril with or without food?

A: According to the official product information, Anafril can be administered orally with or without food. Initial divided doses may be taken with meals to help lessen potential gastrointestinal side effects.

Q: What is the typical half-life of Anafril in the body?

A: The elimination half-life for the parent drug, clomipramine, is approximately 32 hours. Its primary active metabolite, desmethylclomipramine, has a longer half-life, ranging up to approximately 77 hours.

Q: Can Anafril cause excessive sweating (hyperhidrosis)?

A: Yes, regulatory documents list increased sweating (hyperhidrosis) as a commonly observed adverse event. This side effect was reported during clinical trials.

Q: Does Anafril interact with alcohol, and what are the risks?

A: Official warnings state that combining clomipramine with alcohol can increase the effects of the drug. This combination may raise the risk of side effects, including central nervous system (CNS) depression.

Q: Can Anafril be used long-term, and are there long-term side effects?

A: Most controlled clinical trials used to establish the drug’s effectiveness were short-term (typically 10 to 12 weeks). The safety and effectiveness of continuous longer-term use have not been clearly established in controlled studies, so monitoring by a healthcare professional may be utilized for extended treatment.

Q: Can a patient with glaucoma use Anafril safely?

A: Official warnings state that the drug's anticholinergic properties require caution for patients with glaucoma. The medication may exacerbate conditions like angle-closure glaucoma and untreated intraocular hypertension. The decision to use the drug requires careful consideration of the patient's glaucoma status by a healthcare provider.

Q: Does Anafril interact with medications for high blood pressure?

A: The drug may interact with medications that lower blood pressure, such as certain calcium channel blockers. Regulatory documents note that combining them could cause additive effects, potentially leading to an excessive drop in blood pressure.

Q: Why do some people take their entire Anafril dose at bedtime?

A: The total daily dose is sometimes consolidated and given once daily at bedtime. This strategy is used to help minimize common adverse effects, such as sedation and drowsiness, during a person’s waking hours.

Q: Does Anafril affect sleep patterns, causing insomnia or vivid dreams?

A: Yes, official adverse event tables list both insomnia (difficulty sleeping) and abnormal dreaming as reported side effects. These effects are part of the drug’s impact on the nervous system.

Q: Why is Anafril sometimes prescribed for conditions other than OCD or depression?

A: Although the drug is officially approved for Obsessive-Compulsive Disorder (OCD), it has been evaluated in research and clinical settings for symptoms of other conditions. These include symptoms of autistic disorder and cataplexy associated with narcolepsy.

Q: How long does Anafril stay in your system after stopping the medication?

A: Due to the long half-life of the drug and its active metabolite (up to 77 hours), it may take several weeks for the medication to be entirely cleared from the body after a patient stops treatment.

Q: Can Anafril be used by people with a history of liver or kidney problems?

A: Official documents state the drug is strictly contraindicated in patients with severe liver disease. For other forms of liver or kidney impairment, caution may be warranted, as the drug’s processing by the body under these conditions has not been fully determined.

Q: Why is dental care important while taking Anafril?

A: Dental care is important because a very common side effect of Anafril is dry mouth. This condition can lead to complications such as tooth decay (caries) and gum inflammation (gingivitis).

How should Anafril be stored and disposed of?

How to Store and Dispose of Anafril?

Anafranil (clomipramine hydrochloride) must be stored according to specific regulatory requirements to maintain product stability and ensure safety.

Required Storage Conditions

Anafranil should be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The medicine must be kept in the original container and stored tightly closed. It must be protected from excess heat, light, and moisture, and regulatory labeling explicitly states do not freeze. To prevent accidental ingestion, the medication must always be stored out of the sight and reach of children.

Disposal of Unused Product

Official guidelines advise consumers to follow any specific instructions on the labeling. The preferred disposal method is using a community-based drug take-back program. If this is unavailable, unused or expired medicine should be mixed with an undesirable substance, placed in a sealed bag, and thrown into the household trash. Do not flush Anafranil down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anafril found in:

A-Z Index: